Immunomedics awarded F-18 protein labeling patent

Immunomedics, a biopharmaceutical developer of monoclonal antibodies to treat cancer and other diseases, announced that it has received U.S. patent 7,563,433--covering methods and compositions for fluorine-18 (F-18) labeling of proteins, peptides and other molecules.

The patent covers a method for attaching F-18 to peptides via a conjugate with aluminum or other metals, published by the company in the June issue of the Journal of Nuclear Medicine.

The new patent provides coverage until 2027.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.